ヒトマイクロバイオーム治療の世界市場2021年-2031年

◆英語タイトル:Human Microbiome Therapeutics Market Report 2021-2031

visiongainが発行した調査報告書(VGA21MA050)◆商品コード:VGA21MA050
◆発行会社(リサーチ会社):visiongain
◆発行日:2021年1月
◆ページ数:492
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD5,199 ⇒換算¥769,452見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートでは、世界のヒトマイクロバイオーム治療の世界市場について調査・分析し、レポート概要、エグゼクティブサマリー、製品・技術概要、マイクロバイオーム治療開発、市場動向、技術別分析、治療別分析、種類別(糞便微生物叢移植(FMT)、ライブ生物療法製品(LBP)、モノクローナル微生物、人工細菌、調節性マイクロバイオーム治療)分析、製品別分析、地域別分析、競争状況分析、特許分析、臨床試験分析、主要企業情報などの項目を掲載しています。
・レポート概要
・エグゼクティブサマリー
・製品・技術概要
・マイクロバイオーム治療開発
・市場動向
・世界のヒトマイクロバイオーム治療市場規模:技術別
・世界のヒトマイクロバイオーム治療市場規模:治療別
・世界のヒトマイクロバイオーム治療市場規模:種類別(糞便微生物叢移植(FMT)、ライブ生物療法製品(LBP)、モノクローナル微生物、人工細菌、調節性マイクロバイオーム治療)
・世界のヒトマイクロバイオーム治療市場規模:製品別
・世界のヒトマイクロバイオーム治療市場規模:地域別
・競争状況分析
・特許分析
・臨床試験分析
・主要企業情報

What is holding you back in the Human Microbiome Therapeutics Business?

Microbiome therapeutics have emerged as a novel therapeutic strategy, whereby living microbial cells or their components and metabolites are exploited to treat various diseases. Faecal microbial transplants (FMTs) have proved their success in treating recurring Clostridium difficile infections (CDI) for a long time. The potential of microbial therapeutics to address unmet medical needs has, therefore, been attracting many small- and big-players in this area. Still many human microbiome therapeutics companies are unable to make a move and grab this opportunity. In this report we have closely analysed human microbiome therapeutics market to find out a successful way out to grow in this tough crisis too. Buy our report to explore the goldmine areas in the global human microbiome therapeutics market.

Our 490+ page report provides 377 tables, 375 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing human microbiome therapeutics market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Discover sales predictions for the global human microbiome therapeutics market and submarkets

Along with revenue prediction for the overall world market, there are 5 segmentations of the human microbiome therapeutics market, with forecasts for 3 technologies, 6 Therapeutic Area, 3 Types, 4 Products each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global human microbiome therapeutics market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

What all Segments Are Covered in the Report?

Global Human Microbiome Therapeutics Market by Technology (COVID-19 Impact Recovery Analysis Covered)
• Genomics
• Proteomics
• Metabolomics
Global Human Microbiome Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)
• Neurological Disorders
• Dermatological Indications
• Cancers
• Metabolic Disorders
• Gastrointenstinal Disorders
• Other Therapeutic Areas
Global Human Microbiome Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)
• Fecal Microbiota Transplantation (FMT)
• Microbiome Drugs
• Microbiome Rebuilding
• Microbiome Preserving
Global Human Microbiome Therapeutics Market by Product (COVID-19 Impact Recovery Analysis Covered)
• Probiotics & Prebiotics
• Medical Food
• Diagnostic Tests
• Other Product
Global Human Microbiome Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa
Which Key Players Are Leading the Global Market and how much share do they Hold?

The global market for human microbiome therapeutics is ascending and has made significant gains in therapeutic treatments. The players in the human microbiome therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the human microbiome therapeutics market. Several strategies were implemented by key market players between 2015 and Dec 2020. There are over 200 microbiome companies involved in different aspects of microbiome therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Human Microbiome Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
• What is the current size of the overall global human human microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are some of the most prominent human human microbiome therapeutics currently in development?
• What are the main trends that will affect the world human microbiome therapeutics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global human microbiome therapeutics market evolve over the forecasted period, 2021 to 2031?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2021 to 2031?
• Which therapies can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?
Top 20 Leading Players Profiled in the Report
• AbbVie Inc. (AbbVie)
• Bristol-Myers Squibb
• Dow Inc Chemical
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• DuPont de Nemours, Inc.
• Merck & Co. Inc
• Pfizer Inc.
• Vertex Pharmaceuticals
• Evelo Biosciences, Inc.
• Kaleido Biosciences, Inc.
• Seres Therapeutics, Inc.
• PureTech Health PLC
• Nestle S.A.
• Mayo Clinic
• MaaT Pharma SA
• 4D pharma plc (4D)
• Assembly Biosciences, Inc
• F. Hoffmann-La Roche Ltd
• Vedanta Biosciences
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

❖ レポートの目次 ❖

1 Report Overview
1.1 Global Human Microbiome Therapeutics Market Overview
1.2 Study Goals and Objectives
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.1 Key Questions Answered by This Analytical Report Include:
1.2 Who is This Report For?
1.3 Methodology
1.4.1 Primary Research
1.4.2 Secondary Research
1.4.3 Data Sources
1.4 Market Evaluation & Forecasting Methodology
1.5 COIVD-19 Impact Recovery Pattern Analysis
1.4.4 V-Shaped Recovery
1.4.5 U-Shaped Recovery
1.4.6 W-Shaped Recovery
1.4.7 L-Shaped Recovery
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2 Executive Summary
2.1 Key Take Away
3 Human Microbiome Therapeutics Products and Technology Overview
3.1 Introduction to Human Microbiome Therapeutics Products
3.1.1 The Human Microbiome
3.1.2 Gut Microbiome
3.1.3 Oral Microbiome
3.1.4 Skin Microbiome
3.2 Microbiome and Human Health and Disease
3.3 Essential Functions of Human Microbiome
3.4 Technologies Aiding Microbiome Research
3.5 Culturing and Cultivation
3.5.1 Animal Models
3.5.2 Gnotobiotic Animal Models
3.5.3 Engineered Systems
3.5.4 Organoid Cultures
3.5.5 Bioreactors
3.5.6 Microbiome Assaying
3.5.7 Direct Observation
3.5.8 Data Analysis
3.6 Microbiome Therapeutics Disease Areas
3.7 Regulatory Landscape for Microbiome Therapeutics
3.8 Microbiome Research Projects
4 Development of Microbiome Therapeutics
4.1 Additive Microbiome Therapy
4.2 Live Biotherapeutic Products (LBPs)
4.3 Modulatory Microbiome Therapy
4.3.1 Small Molecule Postbiotics
4.3.2 Prebiotics
4.4 Subtractive Microbiome Therapeutics
4.5 Antimicrobial Therapy
4.6 Phage Therapy
5 Market Dynamics
5.1 Overview
5.2 SWOT Analysis
5.3 Drivers of Microbiome Therapeutics Market
5.3.1 High Unmet Medical Need
5.3.2 Growing Understanding of the Microbiome
5.3.3 Positive Investment Environment
5.3.4 Strong Pipeline
5.3.5 Acceptance from Regulatory Authorities
5.4 Challenges for Microbiome Therapeutics Market
5.4.1 Lack of Regulatory Guidance
5.4.2 Product Characterization and Manufacturing Challenges
5.4.3 Hurdles in Preclinical and Clinical Research
5.4.4 Need for Skilled Labor
5.4.5 Emerging Markets
5.4.6 Development of Better Diagnostic Methods
5.4.7 Acquisitions and Partnerships
5.5 Threats to the Microbiome Therapeutics Market
5.5.1 New Government Regulations
5.5.2 Stiff Competition in the Global Market
5.5.3 COVID-19 Pandemic
6 Global Human Microbiome Therapeutics Market
6.1 Global Market Overview
6.2 Global Market Outlook in terms of Value (COVID-19 Impact Recovery Analysis)
6.3 Global Market Outlook by Region (COVID-19 Impact Recovery Analysis)
6.4 Global Market Outlook by Technology
6.4.1 Human Microbiome Therapeutics Technology Overview
6.4.2 Global Human Microbiome Therapeutics Market by Technology (Pre-COVID-19 Analysis)
6.4.3 Global Human Microbiome Therapeutics Market by Technology (Post-COVID-19 Impact Recovery Analysis)
6.5 Global Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
6.6 Global Market Outlook by Type
6.6.1 Fecal Microbiota Transplants (FMTs)
6.6.2 Live Biotherapeutic Products (LBPs)
6.6.3 Monoclonal Microbials
6.6.4 Engineered Bacteria
6.6.5 Modulatory Microbiome Therapeutics
6.6.6 Subtractive Microbiome Therapeutics
6.6.7 Global Market Outlook by Type (Pre-COVID-19 Analysis)
6.6.8 Global Market Outlook by Type (Post-COVID-19 Impact Recovery Analysis)
6.7 Global Market Outlook by Product (COVID-19 Impact Recovery Analysis)
7 North America Human Microbiome Therapeutics Market
7.1 North America Market Overview
7.2 North America Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.3 North America Market Outlook by Country (COVID-19 Impact Recovery Analysis)
7.4 US Market Outlook
7.4.1 US Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.5 Canada Market Outlook
7.5.1 Canada Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.6 North America Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
7.7 North America Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
7.8 North America Market Outlook by Type (COVID-19 Impact Recovery Analysis)
7.9 North America Market Outlook by Product (COVID-19 Impact Recovery Analysis)
8 Europe Human Microbiome Therapeutics Market
8.1 Europe Market Overview
8.2 Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.3 Europe Market Outlook by Country (COVID-19 Impact Recovery Analysis)
8.4 Russia Market Outlook
8.4.1 Russia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.5 Germany Market Outlook
8.5.1 Germany Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.6 UK Market Outlook
8.6.1 UK Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.7 France Market Outlook
8.7.1 France Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.8 Italy Market Outlook
8.8.1 Italy Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.9 Rest of Europe Market Outlook
8.9.1 Rest of Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.10 Europe Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
8.11 Europe Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
8.12 Europe Market Outlook by Type (COVID-19 Impact Recovery Analysis)
8.13 Europe Market Outlook by Product (COVID-19 Impact Recovery Analysis)
9 Asia-Pacific Human Microbiome Therapeutics Market
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.3 Asia-Pacific Market Outlook by Country (COVID-19 Impact Recovery Analysis)
9.4 Japan Market Outlook
9.4.1 Japan Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.5 China Market Outlook
9.5.1 China Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.6 India Market Outlook
9.6.1 India Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.7 South Korea Market Outlook
9.7.1 South Korea Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.8 Australia Market Outlook
9.8.1 Australia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.9 Rest of APAC Market Outlook
9.9.1 Rest of APAC Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.10 Asia-Pacific Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
9.11 Asia-Pacific Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
9.12 Asia-Pacific Market Outlook by Type (COVID-19 Impact Recovery Analysis)
9.13 Asia-Pacific Market Outlook by Product (COVID-19 Impact Recovery Analysis)
10 LAMEA Human Microbiome Therapeutics Market
10.1 LAMEA Market Overview
10.2 LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.3 LAMEA Market Outlook by Country (COVID-19 Impact Recovery Analysis)
10.4 Brazil Market Outlook
10.4.1 Brazil Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.5 Saudi Arabia Market Outlook
10.5.1 Saudi Arabia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.6 South Africa Market Outlook
10.6.1 South Africa Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.7 Mexico Market Outlook
10.7.1 Mexico Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.8 UAE Market Outlook
10.8.1 UAE Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.9 Rest od LAMEA Market Outlook
10.9.1 Rest of LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.10 LAMEA Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
10.11 LAMEA Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
10.12 LAMEA Market Outlook by Type (COVID-19 Impact Recovery Analysis)
10.13 LAMEA Market Outlook by Product (COVID-19 Impact Recovery Analysis)
11 Competitive Landscape Analysis
11.1 Investment in Microbiome Therapeutics
11.2 Public Funding Initiatives
11.3 Private Funding Initiatives
11.3.1 Seventure Partners
11.3.2 Flagship Pioneering
11.4 Collaborations and Partnerships in the Global Market
11.5 Licensing and Manufacturing Agreements
11.6 Mergers and Acquisitions in the Global Market
11.7 Leading Market Players in Microbiome Therapeutics Market
11.8 Leading Market Players in Additive Microbiome Therapeutics Market
11.9 Leading Market Players in Modulatory Microbiome Therapeutics Market
11.10 Leading Market Players in Subtractive Microbiome Therapeutics Market
12 Global Human Microbiome Patent Analysis
12.1 Patent Overview
12.2 Patent Analysis
12.3 Patents by Year
12.4 Patents by Type
12.5 Patents by Disease Type
12.6 Patents by Company
12.7 Patents by Country
12.8 Patents by Assignee
13 Global Human Microbiome Clinical Trial Analysis
13.1 Clinical Trial Analysis by Disease Category
13.2 Share of Clinical Trials
13.3 Clinical Trial Analysis by Treatment Strategy
13.4 Share of Clinical Trials
13.5 Clinical Trial Analysis by Company
13.6 Share of Clinical Trials
13.7 Microbiome Therapeutics in Discovery and Preclinical Development
13.8 Microbiome Therapeutics Clinical Trials in Phase 3
14 Leading Company Profiles
14.1 AbbVie Inc. Company
14.1.1 Company Information
14.1.2 Company Overview
14.1.3 Company Financial Profile
14.1.4 Company Product Offerings
14.1.5 Company Recent Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Company Information
14.2.2 Company Overview
14.2.3 Company Financial Profile
14.2.4 Company Product Offerings
14.2.5 Company Recent Developments
14.3 Dow Inc. Chemical Company
14.3.1 Company Information
14.3.2 Company Overview
14.3.3 Company Financial Profile
14.3.4 Company Product Offerings
14.3.5 Company Recent Developments
14.4 Takeda Pharmaceuticals Company Ltd.
14.4.1 Company Information
14.4.2 Company Overview
14.4.3 Company Financial Profile
14.4.4 Company Product Offerings
14.4.5 Company Recent Developments
14.5 Johnson & Johnson Company
14.5.1 Company Information
14.5.2 Company Overview
14.5.3 Company Financial Profile
14.5.4 Company Product Offerings
14.5.5 Company Recent Developments
14.6 DuPont de Nemours, Inc Company
14.6.1 Company Information
14.6.2 Company Overview
14.6.3 Company Financial Profile
14.6.4 Company Product Offerings
14.6.5 Company Recent Developments
14.7 Merck & Co. Inc Company
14.7.1 Company Information
14.7.2 Company Overview
14.7.3 Company Financial Profile
14.7.4 Company Product Offerings
14.7.5 Company Recent Developments
14.8 Pfizer Inc. Company
14.8.1 Company Information
14.8.2 Company Overview
14.8.3 Company Financial Profile
14.8.4 Company Product Offerings
14.8.5 Company Recent Developments
14.9 Vertex Pharmaceuticals Company
14.9.1 Company Information
14.9.2 Company Overview
14.9.3 Company Financial Profile
14.9.4 Company Product Offerings
14.9.5 Company Recent Developments
14.10 Evelo Biosciences, Inc Company
14.10.1 Company Information
14.10.2 Company Overview
14.10.3 Company Financial Profile
14.10.4 Company Product Offerings
14.10.5 Company Recent Developments
14.11 Kaleido Biosciences Inc Company
14.11.1 Company Information
14.11.2 Company Overview
14.11.3 Company Financial Profile
14.11.4 Company Product Offerings
14.11.5 Company Recent Developments
14.12 Seres Therapeutics Inc Company
14.12.1 Company Information
14.12.2 Company Overview
14.12.3 Company Financial Profile
14.12.4 Company Product Offerings
14.12.5 Company Recent Developments
14.13 PureTech Health PLC Company
14.13.1 Company Information
14.13.2 Company Overview
14.13.3 Company Financial Profile
14.13.4 Company Product Offerings
14.13.5 Company Recent Developments
14.14 Nestle S.A. Company
14.14.1 Company Information
14.14.2 Company Overview
14.14.3 Company Financial Profile
14.14.4 Company Product Offerings
14.14.5 Company Recent Developments
14.15 Mayo Clinic Company
14.15.1 Company Information
14.15.2 Company Overview
14.15.3 Company Financial Profile
14.15.4 Company Product Offerings
14.15.5 Company Recent Developments
14.16 MaaT Pharma SA Company
14.16.1 Company Information
14.16.2 Company Overview
14.16.3 Company Financial Profile
14.16.4 Company Product Offerings
14.16.5 Company Recent Developments
14.17 4D Pharma Plc Company
14.17.1 Company Information
14.17.2 Company Overview
14.17.3 Company Financial Profile
14.17.4 Company Product Offerings
14.17.5 Company Recent Developments
14.18 Assembly Biosciences, Inc Company
14.18.1 Company Information
14.18.2 Company Overview
14.18.3 Company Financial Profile
14.18.4 Company Product Offerings
14.18.5 Company Recent Developments
14.19 F. Hoffmann-La Roche Ltd Company
14.19.1 Company Information
14.19.2 Company Overview
14.19.3 Company Financial Profile
14.19.4 Company Product Offerings
14.19.5 Company Recent Developments
14.20 Vedanta Biosciences Company
14.20.1 Company Information
14.20.2 Company Overview
14.20.3 Company Financial Profile
14.20.4 Company Product Offerings
14.20.5 Company Recent Developments
15 Conclusion & Recommendations
16 Glossary



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ヒトマイクロバイオーム治療の世界市場2021年-2031年(Human Microbiome Therapeutics Market Report 2021-2031)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆